Smn Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Survival Motor Neuron (SMN) protein is encoded by the SMN1 gene on chromosome 5q13.2. It is essential for spliceosomal snRNP biogenesis and is the disease-causing protein in Spinal Muscular Atrophy (SMA). [@liu1997]
Overview
SMN Protein The Survival Motor Neuron (SMN) protein is encoded by the SMN1 gene on chromosome 5q13.
Structure
SMN is a 294-amino acid protein (approximately 38 kDa) with multiple functional domains: [@burghes2009]
Tudor domain: Binds to symmetrically dimethylated arginine residues on Sm proteins
Smn Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Survival Motor Neuron (SMN) protein is encoded by the SMN1 gene on chromosome 5q13.2. It is essential for spliceosomal snRNP biogenesis and is the disease-causing protein in Spinal Muscular Atrophy (SMA). [@liu1997]
Overview
SMN Protein The Survival Motor Neuron (SMN) protein is encoded by the SMN1 gene on chromosome 5q13.
Structure
SMN is a 294-amino acid protein (approximately 38 kDa) with multiple functional domains: [@burghes2009]
Tudor domain: Binds to symmetrically dimethylated arginine residues on Sm proteins
RNP biogenesis: Involved in the formation of various ribonucleoprotein complexes
Axonal mRNA transport: SMN is involved in transporting mRNAs critical for neuromuscular junction function
Role in Disease
Spinal Muscular Atrophy (SMA)
SMA is caused by homozygous deletion or mutation of SMN1, leading to SMN protein deficiency. The disease severity correlates with residual SMN protein levels:
SMA Type 1 (severe): <10% SMN, onset by 6 months, inability to sit
SMA Type 2 (intermediate): 10-30% SMN, onset 6-18 months
SMA Type 3 (mild): 30-50% SMN, onset after 18 months
SMA Type 4 (adult-onset): >50% SMN, mild muscle weakness
Pathogenic Mechanisms
Motor neuron degeneration: Loss of α-motor [neurons](/entities/neurons) in the spinal cord
Muscle denervation: Result of motor neuron loss
Impaired splicing: Defects in snRNP assembly lead to aberrant splicing
Risdiplam (Evrysdi): Small molecule SMN2 splicing modifier
Gene therapy: Additional gene replacement approaches in development
Key Publications
Lefebvre S, et al. (1995). "Identification and characterization of a spinal muscular atrophy-determining gene." Cell 80(1): 155-165.
Monani UR, et al. (1999). "A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2." Human Molecular Genetics 8(7): 1177-1183.
Finkel RS, et al. (2016). "Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy." New England Journal of Medicine 375(5): 172-180.
Background
The study of Smn Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
[Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=SMN1)
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)